Kirn David 4
4 · 4D Molecular Therapeutics, Inc. · Filed Jun 26, 2024
Insider Transaction Report
Form 4
Kirn David
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Option (Right To Buy)
2024-06-24−12,930→ 577,070 totalExercise: $14.42Exp: 2033-12-10→ Common Stock (12,930 underlying) - Sale
Common Stock
2024-06-24$23.10/sh−12,930$298,711→ 1,059,153 total - Exercise/Conversion
Common Stock
2024-06-24$14.42/sh+12,930$186,451→ 1,072,083 total
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.
- [F2]The transaction was executed in multiple trades in prices ranging from $22.69 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.